Media

Björn Westberg to join BONESUPPORT™ as Chief Financial Officer

GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH

BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board

Orexo appeal Zubsolv® US district court decision

Nordic Nanovector – Private placement successfully completed

Altimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016

Nordic Nanovector: Betalutin® in combination with rituximab demonstrates synergistic anti-tumour effect in preclinical non-Hodgkin lymphoma model

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients